Caris Life Sciences,�Inc. CAI
31.98
(0.29)
(0.90%)
as of 25 Sep
- Market cap
- $9.1B
- P/E
- 85.1×
Follow CAI
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 15.45% | 45.75% | 0.00% | 0.00% |
+6 more TTM periods Free account |
|
| 7.39% | (75.00%) | (95.58%) | (139.72%) | ||
ROIC |
49.95% | 44.67% | 18.05% | (66.54%) | |
Return on Tangible Assets |
8.39% | (45.74%) | (57.61%) | (82.65%) | |
Average Days of Receivables |
43.11 | 36.41 | 50.41 | 15.70 | |
Free Cash Flow per Share |
0.44 | 0.44 | 0.40 | (0.05) | |
Free Cash Flow |
123.96 | 123.46 | 66.90 | (14.01) | |
Capital Expenditures |
(44.60) | (23.91) | (16.26) | (13.46) | |
Piotroski F-Score |
6.00 | 1.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
9.48% | 8.19% | 4.73% | (0.03%) | |
Accounts Receivable Turnover |
11.80 | 10.15 | 0.00 | 0.00 | |
Accounts Payable Turnover |
5.23 | 5.82 | 0.00 | 0.00 | |
Inventory Turnover |
3.65 | 4.90 | 0.00 | 0.00 | |
Average Days of Payables |
104.53 | 89.76 | 52.44 | 41.01 | |
Days of Inventory on Hand |
150.49 | 98.10 | 85.11 | 69.72 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
11.84% | 12.11% | 12.51% | 15.69% | |
Selling, General and Administrative Expense of Revenue |
42.34% | 44.67% | 48.33% | 59.51% | |
Share Based Compensation of Revenue |
6.58% | 7.85% | 8.62% | 9.88% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.09 | (0.34) | (0.15) | 0.00 | |
Depreciation/Fixed assets |
0.28 | 0.41 | 0.56 | 0.65 | |
Capex/Depreciation |
(1.67) | (0.70) | (0.46) | (0.32) | |
Revenue per Share |
3.50 | 3.21 | 4.86 | 2.20 | |
Operating CF per Share |
0.60 | 0.52 | 0.50 | 0.00 | |
Capex per Share |
(0.16) | (0.08) | (0.10) | (0.05) | |
Capex to Sales |
0.05 | 0.03 | 0.02 | 0.02 | |
Net Profit Margin |
8.15% | (48.04%) | (66.25%) | (110.81%) |
Columns are period end dates